FDA Brief

Warning letters Food

FDA warning letter to

Lipotriad LLC

LowIssued Mar 19, 2021Posted Mar 30, 2021Division of Human and Animal Food Operations East II

FDA warned Lipotriad LLC that its eye vitamins are unapproved new drugs and misbranded due to disease-prevention claims online.

What happened

FDA reviewed Lipotriad's website and Facebook and Twitter pages in November 2020. FDA found claims that the eye vitamin products prevent or treat diseases such as macular degeneration, cataracts, glaucoma, blindness, and dry eye, making them drugs. FDA also said the products are unapproved new drugs and misbranded because they lack adequate directions for those disease uses.

What FDA found

  1. Website and social media claims that the eye vitamins prevent or treat eye diseases make the products drugs.

    FD&C Act section 201(g)(1)(B) [21 U.S.C. 321(g)(1)(B)]
  2. The products are unapproved new drugs because they are not generally recognized as safe and effective for the claimed disease uses.

    FD&C Act sections 201(p), 301(d), and 505(a) [21 U.S.C. 321(p), 331(d), 355(a)]
  3. The products are misbranded because they lack adequate directions for use for their intended disease uses.

    FD&C Act section 502(f)(1) [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
  4. Selling the misbranded products in interstate commerce violates the Act.

    FD&C Act section 301(a) [21 U.S.C. 331(a)]

What FDA wants

FDA asks Lipotriad to notify it in writing within 15 working days of receipt about steps taken to correct the violations and prevent recurrence, with supporting documents. If corrections cannot be completed in that time, the company must state why and give a completion timeframe.

Who should pay attention

  • dietary supplement brands with eye-health claims
  • companies making disease-prevention claims on websites or social media
  • marketers of vitamins sold as supplements

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk